Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 August 2021 | Story Ruan Bruwer | Photo Roger Sedres (Gallo Images)
Louzanne Coetzee and her guide Estean Badenhorst won the silver medal in the 1 500 m in a new African time at the Paralympics in Tokyo on Monday.

It’s been eight years of waiting, but Louzanne Coetzee will finally hang a medal around her neck, and this on the biggest sporting stage in the world.

Coetzee won the silver medal in the 1 500 m women’s T11 final at the Paralympics in Tokyo on Monday (30 August 2021) morning. In the process, she and her guide, Estean Badenhorst, set a new African record (4:40.96).

They are both former University of the Free State (UFS) students, and Coetzee is a resident on the Bloemfontein Campus. 

“I have been competing for eight years and this is my first medal. I’m just overwhelmed. I couldn’t have asked for a better race, a better guide, and better preparation. I’m just very thankful for how everything went down,” Coetzee said.
The race took place at 32 degrees with a humidity percentage of 70 plus. Coetzee’s time was only 2.04 seconds off the previous world record. 

She has had a stunning Games so far. In Sunday’s heat, she improved her personal best from 4:51.65 to 4:49.24 and ran another eight seconds quicker on Monday.

It was also a personal triumph for Coetzee, who experienced the disappointment of being disqualified five years ago at the Rio Games, after a ruling that her guide had stepped in front of her. 

Prof Francis Petersen, UFS Rector and Vice-Chancellor, saluted Coetzee. “We are tremendously proud of what she has achieved throughout her athletics career. She has represented the country numerous times at international sport events and winning a silver medal and setting a new African record is the culmination of hard work and exceptional endurance.” 

“The entire university community was rooting for her; she has done us and her country extremely proud,” Prof Petersen said.

Coetzee still has the T12 marathon on Sunday on her schedule.

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept